Citigroup Inc Cabaletta Bio, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Citigroup Inc holds 34,566 shares of CABA stock, worth $79,156. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,566

Previous 22,894 50.98%

Holding current value

$79,156

Previous $171,000 4.68%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$3.94 - $8.24 $45,987 - $96,177	11,672 Added 50.98%	34,566 $163,000
Q2 2024 Aug 12, 2024	SELL	$7.22 - $18.82 $2.01 Million - $5.25 Million	-278,992 Reduced 92.42%	22,894 $171,000
Q1 2024 May 10, 2024	BUY	$16.79 - $25.38 $3.62 Million - $5.47 Million	215,340 Added 248.82%	301,886 $5.15 Million
Q4 2023 Feb 09, 2024	BUY	$12.21 - $23.36 $449,950 - $860,839	36,851 Added 74.15%	86,546 $1.96 Million
Q3 2023 Nov 09, 2023	BUY	$11.84 - $18.65 $498,203 - $784,754	42,078 Added 552.42%	49,695 $756,000
Q2 2023 Aug 10, 2023	SELL	$7.65 - $13.95 $291,732 - $531,983	-38,135 Reduced 83.35%	7,617 $98,000
Q1 2023 May 11, 2023	BUY	$7.08 - $12.62 $323,924 - $577,390	45,752 New	45,752 $378,000
Q3 2022 Nov 10, 2022	SELL	$0.63 - $2.05 $61 - $198	-97 Reduced 22.2%	340 $0
Q2 2022 Aug 10, 2022	SELL	$0.99 - $2.11 $1,345 - $2,867	-1,359 Reduced 75.67%	437 $0
Q1 2022 May 12, 2022	SELL	$1.68 - $3.92 $1,120 - $2,614	-667 Reduced 27.08%	1,796 $4,000
Q4 2021 Feb 10, 2022	BUY	$3.36 - $14.64 $1,565 - $6,822	466 Added 23.34%	2,463 $9,000
Q3 2021 Nov 10, 2021	BUY	$7.0 - $12.5 $13,979 - $24,962	1,997 New	1,997 $24,000

Others Institutions Holding CABA

# of Institutions

126

Shares Held

47.9M

Call Options Held

202K

Put Options Held

110K

View Full List

About Cabaletta Bio, Inc.

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $66.4M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

More about CABA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account